You are here

Article Text

Article menu
Download PDFPDF
Letter
Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population
  1. Eva Doorakkers1,
  2. Jesper Lagergren1,2,
  3. Lars Engstrand3,4,
  4. Nele Brusselaers3,4,5
  1. 1 Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
  2. 2 Division of Cancer Studies, King’s College London, London, UK
  3. 3 Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
  4. 4 Sciencefor Life Laboratory (SciLifeLab), Stockholm, Sweden
  5. 5 Ghent University, Ghent, Belgium
  1. Correspondence to Dr Nele Brusselaers, Department of Molecular Medicine and Surgery, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm 17176, Sweden; nele.brusselaers{at}ki.se

https://doi.org/10.1136/gutjnl-2019-319000

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We recently discovered that we used a suboptimal method for a part of our statistical analyses in our paper published recently in Gut.1 This has affected the duration analyses (time since eradication of Helicobacter pylori) and associated risk of gastric cancer. Previously, we only assessed the risk of gastric cancer in those eradicated during the selected follow-up periods, and disregarded the other individuals who ideally should also have contributed person-time. …

    View Full Text